Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1988 2
1989 1
1990 1
1992 1
1993 3
1994 2
1996 1
1997 5
1998 4
1999 4
2000 6
2001 2
2002 3
2003 3
2004 6
2005 6
2006 12
2007 10
2008 9
2009 5
2010 6
2011 11
2012 15
2013 11
2014 13
2015 15
2016 16
2017 15
2018 12
2019 12
2020 9
2021 9
2022 8
2023 11
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Results by year

Filters applied: . Clear all
Page 1
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
Ruiz-Cobo JC, Llaneras J, Forns X, Gallego Moya A, Conde Amiel I, Arencibia A, Diago M, García-Samaniego J, Castellote J, Llerena S, Rodríguez-Seguel E, Mateos B, Rodríguez M, Rosales Zabal JM, Fernández I, Calleja JL, Morillas RM, Montoliu S, Andrade RJ, Badia Aranda E, Hernández-Guerra M, Maté CJ, González-Santiago JM, de Cuenca B, Bernal-Monterde V, Delgado M, Turnes J, Lens S, Buti M. Ruiz-Cobo JC, et al. Among authors: diago m. Aliment Pharmacol Ther. 2024 May 2. doi: 10.1111/apt.18020. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 38695095
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.
Ampuero J, Aller R, Gallego-Durán R, Crespo J, Calleja JL, García-Monzón C, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Albillos A, Francés R, Fernández-Rodríguez C, Maya-Miles D, Diago M, Poca M, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Hernández-Guerra M, Pareja-Megia MJ, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Turnes J, Romero-Gómez M; HEPAmet Registry. Ampuero J, et al. Among authors: diago m. J Gastroenterol. 2024 Apr 15. doi: 10.1007/s00535-024-02098-8. Online ahead of print. J Gastroenterol. 2024. PMID: 38619600
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
Younossi ZM, Alqahtani SA, Alswat K, Yilmaz Y, Keklikkiran C, Funuyet-Salas J, Romero-Gómez M, Fan JG, Zheng MH, El-Kassas M, Castera L, Liu CJ, Wai-Sun Wong V, Zelber-Sagi S, Allen AM, Lam B, Treeprasertsuk S, Hameed S, Takahashi H, Kawaguchi T, Schattenberg JM, Duseja A, Newsome PN, Francque S, Spearman CW, Castellanos Fernández MI, Burra P, Roberts SK, Chan WK, Arrese M, Silva M, Rinella M, Singal AK, Gordon S, Fuchs M, Alkhouri N, Cusi K, Loomba R, Ranagan J, Eskridge W, Kautz A, Ong JP, Kugelmas M, Eguchi Y, Diago M, Yu ML, Gerber L, Fornaresio L, Nader F, Henry L, Racila A, Golabi P, Stepanova M, Carrieri P, Lazarus JV; Global NASH Council. Younossi ZM, et al. Among authors: diago m. J Hepatol. 2024 Mar;80(3):419-430. doi: 10.1016/j.jhep.2023.11.004. Epub 2023 Nov 18. J Hepatol. 2024. PMID: 37984709
Extrarenal fibrillary glomerulonephritis as an unknown etiology of advanced liver disease.
Alventosa Mateu C, Vilar Gimeno A, Pérez Álvarez I, Carbonell Zamorano J, Castelló Miralles I, Latorre Sánchez M, José Urquijo Ponce J, Martínez Leandro E, Terrádez Mas L, Diago M. Alventosa Mateu C, et al. Among authors: diago m. Gastroenterol Hepatol. 2024 Apr;47(4):381-383. doi: 10.1016/j.gastrohep.2023.08.002. Epub 2023 Aug 9. Gastroenterol Hepatol. 2024. PMID: 37562769 English, Spanish. No abstract available.
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Yuen MF, Asselah T, Jacobson IM, Brunetto MR, Janssen HLA, Takehara T, Hou JL, Kakuda TN, Lambrecht T, Beumont M, Kalmeijer R, Guinard-Azadian C, Mayer C, Jezorwski J, Verbinnen T, Lenz O, Shukla U, Biermer M; REEF-1 Study Group. Yuen MF, et al. Lancet Gastroenterol Hepatol. 2023 Sep;8(9):790-802. doi: 10.1016/S2468-1253(23)00148-6. Epub 2023 Jul 10. Lancet Gastroenterol Hepatol. 2023. PMID: 37442152 Clinical Trial.
220 results